Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer Recurrent: early-phase trial registry
3 of 7 indexed Prostate Cancer Recurrent trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Prostate Cancer Recurrent: 7 US clinical trials tracked, 3 recruiting.
Prostate Cancer Recurrent is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is RhoVac APS, running 1 of these trials.
Enrollment posture brief
Registry condition prostate-cancer-recurrent
OPEN 3 | RECR 43% | LATE 1 | EARLY 6 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)
Prostate Cancer Recurrent lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer Recurrent on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer Recurrent is recruiting below its size-band peers.
3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer Recurrent trials is spread across many organizations.
RhoVac APS accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer Recurrent enrolment sits around 76 participants.
Median target enrolment is 76 among the 7 trials that report a genuine target (sentinel values excluded). 4 of those (57.1%) plan for fewer than 100 participants.
-
Prostate Cancer Recurrent research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Clarity Pharmaceuticals
NCT06970847
COAST Therapy in Advanced Solid Tumors and Prostate Cancer
Medical University of South Carolina
NCT05036226
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
Shehzad Basaria, M.D.
NCT06957691
Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer
RhoVac APS
NCT04114825
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
MacroGenics
NCT05848011
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Five Eleven Pharma
NCT03444844
Metformin Prostate Cancer Adjuvant Trial
NYU Langone Health
NCT02176161
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Cancer Recurrent records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Cancer Recurrent trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Cancer Recurrent page
7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Prostate Cancer Recurrent trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- RhoVac APS sponsors the most Prostate Cancer Recurrent trials on record, review their full trial history before evaluating a specific study. See RhoVac APS's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Cancer Recurrent condition card totals 7 registered trials; most-linked intervention Metformin Hydrochloride Extended Release 750mg; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.